EGFR and neoplasm: In early stage lung cancer patients (stages IA–IIIA), it was shown that deep sequencing for ctDNA resulted in a low sensitivity of 36.5% in detecting the EGFR (L858R) mutation present in the tumor tissue, whereas this increased to 72.7% in metastatic setting (stages IIIB–IV) [84].